MedTrace Logo

Exercise and Protein Efficiency in T2D

NCT07477067 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-29

No results posted yet for this study

Summary

In this randomized controlled trial, 30 older adults (aged\> 65 years; 15 with T2D, 15 controls) will participate in a 12-week progressive exercise training program. They will undergo pre- and post-testing that includes body composition measures; oral glucose tolerance testing; cardiovascular fitness and muscle performance testing; dietary protein efficiency assessed using the indicator amino acid oxidation (IAAO) method; and a gut microbiota trial. The dietary protein efficiency trial will include repeated ingestion of crystallized amino acids (drink) containing stable isotopes, urine samples, and breath samples. The gut microbiome trial will consist of a single ingestion of a Mediterranean-based modeled meal enriched with 13C-phenylalanine (in the drink) and repeated blood draws. Participants will also be asked to give a fecal sample after the gut microbiome trial.

Conditions

Interventions

OTHER

12 week progressive exercise training

moderate - to - vigorous aerobic and strength-based exercise training will be performed 2-3 times per week for 12 weeks. Strength Training consists of a 5-minute warm-up on a stationary bike, followed by 1-3 sets on the leg press, leg extension, and leg curl machines. In addition, participants will preform upper body exercises on guided motion machines (seated chest press, shoulder press, seated rows) on alternate training days. Training intensity will gradually increase on each participants comfort level. Endurance training will be performed on a stationary bike. Exercise intensity will be controlled by heart rate and rate of perceived exertion (RPE) using the Borg's original scale (6-20 points). Weeks 1--3 will be at 50-60% of max heart rate for 30 minutes; weeks 4-6 will be at 50-60% of max heart rate for 40 minutes; weeks 7-9 will be 60-70% of max heart rate for 50 minutes; and weeks 10-12 will be at 60-70% of max heart rate for 60 minutes.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-09
Primary Completion
2027-06-30
Completion
2028-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07477067 on ClinicalTrials.gov